doripenem has been researched along with ceftriaxone in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (60.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Appelbaum, PC; Credito, KL; Ednie, LM | 1 |
Brown, NP; Pillar, CM; Sahm, DF; Shah, D; Torres, MK | 1 |
Bell, JM; Castanheira, M; Jones, RN; Mathai, D; Turnidge, JD | 1 |
Carmeli, Y; Chmelnitsky, I; Goren, MG; Navon-Venezia, S | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for doripenem and ceftriaxone
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for doripenem and ceftriaxone
Article | Year |
---|---|
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Carbapenems; Colony Count, Microbial; Doripenem; Humans; Microbial Sensitivity Tests | 2008 |
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; United States | 2008 |
Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
Topics: Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Humans; India; Microbial Sensitivity Tests; Molecular Sequence Data; Prevalence; Pseudomonas aeruginosa; Ribotyping | 2009 |
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
Topics: Academic Medical Centers; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; DNA Primers; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Escherichia coli; Escherichia coli Infections; Humans; In Vitro Techniques; Israel; Microbial Sensitivity Tests; Molecular Epidemiology; Plasmids; Time Factors | 2010 |